Member Info for Jatw

Hope they will come with some clear plans to deliver sh value...
Dividends not buy backs please.....

I would rather buy buy buy.
HY results in a couple of weeks.....value to be unlocked by M&GPrudential demerger. Would not be surprised to see £20 for the pair of shares shortly after demerger..

Sp has risen significantly in recent weeks, time for a breather....or some accumulation...
The dynamics of this market point to a bright future. Higher spending on private healthcare for pets.....and consolidation of small practices into larger groups such as cvsg.
I would also buy veterinary pharma companies.

Momentum is good 3m chart heading upwards.....maybe a new trading range of 16-19 will become established after the last few years in the 14-16 range....

Still need to start generating significantly more cash to start raining the dividend...would be nice confidence signal to see the q4 divi increased.....only has to be a little..

https://finance.yahoo.com/video/astrazeneca-open-m-sales-forecast-085559133.html
AZN CEO speaks about strong sales in China and ongoing investment in innovative products..
AZN infrastructure development should be good for Savo once approved..

I expect there will be a gradual recovery....once the underwriters have managed to place the shares.....given the reaction to the placing, I suspect the appetite to test the market in 90 days time in HK with a small dilution is limited.....
Either HCM will run down its cash reserves for 6-12 months or issue a bond perhaps secured on Elunate royalties.....

The key is positive developments with Surufatinib and savolitinib studies and getting Elunate on the drug reimbursement programme. All possible this year.
For those looking long term, I expect this is a good buying opportunity.

The CKHH accounts will not show the loss.....they will show a profit because under historical cost accounting they will be holding their investment at only a few hundred million. The unrealised profit will be a balance sheet movement.
Anyway....if HCM prospers the new buyers of these shares will make a handsome profit.....and our investments will recover their previous value and more......

Financial services in Africa will be a significant growth area. Individual markets are beginning to achieve widespread income levels that create protection and investment needs.....Asia has been going through this income growth....when it takes off in Africa the internet and more modern technology will mean it happens faster and stronger than in Asia...that is why I hold OMU...

It is the hope that things will prove that hurts

5yr SP has fallen 80p......dividend about 120p..taxed at 32% means TSR of about zero for the last five yes five years........negative returns for many......just not good enough.

BB you are correct HHH is just above 50% and the exercise of the option would take them below to their desired outcome. 30 days from 28 June (calendar days expires on sun 28 July, working days around 9 August plus maybe some holidays).
If that does not take place HHH will have lost 30% of market value of its investment (for its HY19 accounts) and not achieved what it wanted.
The HHH stake presale was worth about $2.4b, it has been turned into a stake of $1.4b and $270m cash so a loss of value to HHH and CKHH of about $730m.
As a CKHH shareholder as well as HCM sh you could say I am very disappointed and there should be consequences for the management of HHH and CKHH (and their advisors).

Updates look positive for the future, with new manufacturing and distribution deals.

However nothing to say on revenue or margins in H1 so assume these are not changed.....or mildly negative.....have to wait for the accounts.

A long term play this one...can’t see much movement for 6 months but the FY numbers should show impact of revenue growth. Looking for some upward movement in March post FY results.

The update was excellent......but shares are down a bit.....makes you wonder what a company has to do to get a bump up? Maybe that will happen with the actual results and increase in dividend.

DCR I hope you are right...
We will need to read the CKHH accounts carefully to see why they did sell as they seem to have done themselves no favours with the discount required to get the sale away, but it probably ensured that The underwriter would exercise the option for more shares so that the shareholding falls below 50%.
I think the sale says more about CKHH than HCM. CKHH does not want the increasing HCM losses in its P&L nor any associated debt funding on its balance sheet.

It will be interesting when the placing comes whether HHH then keeps its share at 49.8 or let’s it fall further. They did buy in to the NASDAQ listing and it would be positive for them to buy into any HK listing.

I am sure that the dominant shareholder will have considered a full sale and may receive unsolicited offers from time to time....at the moment there are a lot of assumptions about the pipeline that make it less likely a bidder would pay the premium required to force a sale (GSK paid nearly twice the market price for Tesaro)...it probably does not help a bid that the main products are partnered, any acquirer would need to continue these relations or may have to sell assets back to Lilly or AZ..

CKHH appears content to support the business through its growth phase, but note it has not made pharma a formal subdivision of its business....indicating it might be for sale for the right price.

Well it would help if there some news to drive the SP.....
The review of the back book might be interesting but it depends what it does with the cash......SLAs sale of its back book while retaining a significant stake in Phoenix is one of the reasons for recent upgrades.....but the core business is not firing which is their problem.
We are nearing the HY results which will be an opportunity to appraise the core of Quilter.

Nothing obvious and the sp recovered in the afternoon.....not the only aim share to act that way.
These days a trading statement is like Russian roulette.

Management seems to be focusing on the basics again.....still plenty of growth out there.....spending per pet is increasing and as insurance penetration increases there will be more spent on expensive procedures.
SP now at reasonable levels so looking forward to more steady progress.

Will we get one in the next 2 weeks.....quite likely as HY update was issued on 15 Jan.

As a listed (and frequently strongly performing) company, HL should expect its shares to be over represented in some of the best performing funds it sells to clients and it will be held in funds operated by competitors (just as Pru, Lgen, Aviva will have holdings in each other].
I am not sure what message they are giving the market by removing LT for having too much HL stock. One could take an inference that HL is overvalued and hence LT is going to underperform....but that does not appear to be it. Would it not have been better to list out the funds owning HL stock (including trackers) and then set out policy that these investors have no inside access to HL and that the wealth fund listings consider concentration risk as a risk to future performance....the FMs will get the message that some overweight in a share like HL is OK but betting the house on a small number of stocks is not.
Being whiter than white could have unintended consequences- LT May now sell out of HL (if they do, then speculators will short the stock, just as they have Woodford holdings which all results in a much lower SP)